27 articles with Aptinyx
Aptinyx to Present Preclinical Data on Three Clinical-Stage NMDA Receptor Modulators at the 49th Annual Meeting of the Society for Neuroscience
The poster presentations will highlight preclinical data from three of Aptinyx’s clinical-stage product candidates that are in development for chronic pain, PTSD, and cognitive impairment.
Shares of Illinois-based Aptinyx Inc. have plunged more than 67 percent in premarket trading after the company announced its mid-stage treatment for painful diabetic peripheral neuropathy failed to show statistical significance.
Aptinyx Completes Enrollment in Phase 2 Study of NYX-2925 for Painful Diabetic Peripheral Neuropathy
Top-line Data Expected Early in the First Quarter of 2019
10/15/2018Depression affects almost 20 million Americans yearly and major depressive disorders affect nearly 300 million people worldwide. The annual market for these disorders is approximately $83 billion.
Aptinyx Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Aptinyx Inc. announced the closing of its initial public offering of 7,359,998 shares of common stock at a public offering price of $16.00 per share
6/22/2018Autolus Therapeutics snagged $150 million from its initial public offering, about $25 million more than the company initially expected when it began its roadshow effort earlier this month.
It’s a super-busy week for biotech initial public offerings (IPOs) with six companies raking in a total of around $568 million.
Pricing of its initial public offering of 6,399,999 shares of its common stock at a public offering price of $16.00 per share.
Axial Biotherapeutics today announced the appointment of renowned researchers and thought leaders with expertise in neurology, Parkinson’s disease and regulatory strategy to its scientific and clinical advisory board.
5/29/2018It’s been a busy month for IPOs. Numerous biotech companies announced their intentions to publicly list their stock on an exchange in the U.S. or abroad in order to gain new funding to advance developmental programs.
A day after Illinois-based Aptinyx strengthened its relationship with pharma giant Allergan, the company is now eying an $80 million initial public offering of stock on the Nasdaq Exchange.
Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research Collaboration
Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced Allergan plc (NYSE: AGN) has exercised its option to acquire drug candidate AGN-241751, an oral small-molecule N-methyl-D-aspartate (NMDA) receptor modulator
Allergan has exercised an option to acquire an oral small molecule compound from Illinois-based Aptinyx, a spinout of Naurex, Inc., which the Irish company acquired in 2015. The company will use it as a complement to a Phase III depression treatment.
Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced that David R. Houck, Ph.D. has been promoted to chief development officer.
Aptinyx Presents Data on NMDA Receptor Modulator NYX-458 in a Preclinical Model of Parkinson's Cognitive Impairment at the AAT-AD/PD Focus Meeting 2018
Aptinyx Inc. announced the presentation of preclinical data that supports advancing the development of a novel N-methyl D-aspartate (NMDA) receptor modulator, NYX-458, as a treatment for cognitive impairment associated with Parkinson's disease.
Aptinyx Presents Preclinical and Phase 1 Clinical Data from NYX-2925 at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics
Aptinyx Inc. announced they will present preclinical and early-stage clinical data from studies of the company's lead product candidate, NYX-2925, at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics, March 7-10, 2018 in Rockville, MD.
Aptinyx Presents NYX-2925 Preclinical Data in Chemotherapy-induced Neuropathic Pain at the American Pain Society Annual Scientific Meeting
Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced their presentation at the American Pain Society's Annual Scientific Meeting, March 4-6, 2018 in Anaheim, CA.
Mr. Khanna has served as chief business officer of Aptinyx since the company's inception in 2015.
The round was led by Bain Capital Life Sciences.
Aptinyx Granted Fast Track Designation, Initiates Phase I for Second Clinical Candidate, NYX-783, in Post-Traumatic Stress Disorder
The U.S. Food and Drug Administration has granted Aptinyx Fast Track designation for the development of NYX-783 for the treatment of PTSD.